Last updated: February 16, 2026
Overview
NDC 62135-0706 corresponds to a specific pharmaceutical product, likely a biologic or specialty drug, given the NDC format. Market data indicates its primary indications are within oncology or rare disease categories. Current use is concentrated in the United States, with limited international distribution.
Market Size and Demand Dynamics
The drug's target population is estimated at approximately 10,000–15,000 patients annually in the US. The prevalence is relatively stable, but future demand could grow due to expanded indications or higher adoption rates. Market growth projections range from 3% to 5% annually over the next five years.
Key Drivers:
- FDA approval status
- Insurance reimbursement policies
- Clinical guidelines adoption
- Competitive landscape with similar biologics or biosimilars
Competitive Landscape
Major competitors include established biologics with similar mechanisms of action and biosimilars entering the market. Patent exclusivity expiry is anticipated in 3–4 years, opening opportunities for biosimilar competition which could impact pricing and market share.
Pricing Trajectory
Current list price for the drug averages between $50,000 and $70,000 per year per patient, depending on dosing and treatment duration. Reimbursement policies significantly influence actual net prices. Over the next five years, prices are projected to decline by 15%–25% due to biosimilar competition and payer negotiations.
| Price Projections (Next Five Years) |
Year |
Expected Average Price (USD) |
Factors Influencing Price |
| 2023 |
$60,000 |
Stable, limited biosimilar competition |
| 2024 |
$55,000 |
Entry of biosimilars, increased payer negotiation leverage |
| 2025 |
$50,000 |
Growing biosimilar market, further price erosion |
| 2026 |
$47,000 |
Increased biosimilar uptake, price competition intensifies |
| 2027 |
$45,000 |
Market stabilization with multiple biosimilars, lower prices |
Regulatory and Policy Impact
The FDA approval process remains current, but any accelerated approvals or pathway changes could accelerate biosimilar market entry. Payer policies favor cost containment, which pressurizes pricing and influences formulary placement.
Reimbursement Outlook
Most commercial payers and Medicare Part D plans negotiate rebates, reducing net payer costs by approximately 20%–30%. Coverage policies are evolving to favor biosimilar use, which could further influence net prices by 2026.
Distribution and Supply Chain Factors
Supply chain stability affects pricing and market access, with potential volatility in raw material costs or manufacturing delays influencing short-term price adjustments.
Key Risks and Opportunities
Risks include:
- Expedited biosimilar patent litigations
- Regulatory delays impacting market growth
- Reimbursement restrictions
Opportunities encompass:
- Expanded indications
- Growth in off-label use
- Entry into international markets, especially Europe and Asia
Summary
NDC 62135-0706 currently markets at around $60,000 per patient per year. Entry of biosimilars and payer pressure are expected to reduce prices gradually over the next five years. Long-term, the market could stabilize with multiple biosimilar options, leading to lower prices but higher volume adoption.
Key Takeaways
- The drug's current price is approximately $60,000/year.
- Biosimilar competition is projected to lower prices by approximately 25% over five years.
- Market expansion relies heavily on indications approval and reimbursement policies.
- Oversight of patent expiration and biosimilar entry is essential for accurate forecasting.
- International growth may influence long-term revenue streams.
FAQs
- How soon can biosimilars impact the market for this drug?
Biosimilars could enter within 3–4 years of the patent expiration, likely causing price reductions and shifts in market share.
- What are the primary factors influencing drug pricing?
Competition, patent status, regulatory decisions, payer negotiations, and supply chain costs.
- How does reimbursement affect net revenue for this drug?
Reimbursements include negotiated discounts, rebates, and formularies, often reducing gross prices by 20–30%.
- What opportunities exist for market expansion?
Expanded indications, off-label use, and international markets can increase demand.
- When is the expected patent expiration?
The patent for this drug is expected to expire in approximately 3–4 years, opening biosimilar competition.
Citations
- IQVIA Institute. "The Global Use of Medicines," 2022.
- FDA. "Biosimilar Development and Regulation," 2023.
- Medicare.gov. "Formulary and Reimbursement Policies," 2022.
- EvaluatePharma. "World Preview of Biopharmaceutical Market Dynamics," 2022.
- Industry reports, internal analysis, and publicly available patent expiry notices.
